<DOC>
	<DOCNO>NCT00427154</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . This trial compare change HbA1c 26 week inhaled insulin rosiglitazone treatment , combination metformin glimepiride .</brief_summary>
	<brief_title>Effect Inhaled Pre-prandial Human Insulin Blood Glucose Control Type 2 Diabetes</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes Currently treat antidiabetes drug ( include Exenatide ) least 2 month HbA1c 7.5 11.0 % ( inclusive ) antidiabetes combination therapy BMI le equal 40 kg/m2 Current smoking smoking within last 6 month Current acute chronic pulmonary disease ( except asthma ) Proliferative retinopathy require acute treatment Clinically significant disease history include kidney liver disease Heart disease limit physical activity result discomfort physical activity Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>